Press Release Archive

Click here for Current Press Releases

Disclaimer

The following archived materials by HepaLife Technologies, Inc. contain information believed to be accurate when produced and posted but that may have been superseded by subsequent events and the passage of time. Accordingly, when reviewing this information please note that the information was created as of the date listed, reflected management views as of that date, should be considered in the context of the circumstances prevailing at that time and is only correct as of that date.

The information contains certain forward-looking statements that are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to, the Risk Factors noted in HepaLife Technologies, Inc. latest annual report on Form 10K and HepaLife Technologies, Inc. other filings and submissions with the Securities and Exchange Commission.

HepaLife Technologies, Inc. assumes no obligation to update the information in this section to reflect developments which may have occurred after the date of this information. By viewing these archived materials, you acknowledge that you understand this cautionary statement.

Date	Title
01/22/2008	HepaLife™ Announces Appointment of Dr. Christopher W. Kemp, Vice President of Research & Development
12/17/2007	HepaLife™ Surpasses Significant Milestones in Development of Artificial Liver Device
11/27/2007	HepaLife™ Enters Into New Cooperative Research and Development Agreement with U.S. Government Agency
11/08/2007	HepaLife™ Announces Exclusive License Agreement with U.S. Government Agency for Liver Cell Lines
09/26/2007	HepaLife™ Releases Positive New Research Results For First-of-its-Kind Bioartificial Liver
08/21/2007	Internationally Renowned Artificial Organs Expert Joins HepaLife™
08/13/2007	HepaLife™ Bioartificial Liver: Analysts Forecast Artificial Liver Market to Surpass $2.7 Billion by 2010
07/09/2007	HepaLife Expands Scientific Team and Continues Development of First-of-its-Kind Artificial Liver Device
06/25/2007	HepaLife’s PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
05/29/2007	HepaLife Announces Scientific Presentation Of PBS-1 Cell Line At International Influenza Meeting.
05/15/2007	HepaLife Completes Private Placement for $2.5 Million.
05/08/2007	HepaLife Expands Management Team on Heels of Favorable Outcomes of First-of-its-Kind Bioartificial Liver Device.
04/30/2007	HepaLife Achieves Major Milestone in Development of Artificial Liver Device.
04/10/2007	HepaLife's Cells for Artificial Liver Device Significantly Outperform Most-Widely Used Human Liver Cell Line.
03/28/2007	HepaLife's Patented 'PBS-1' Cells for Avian Flu Vaccines Outperform Current Cell System by 500%.
03/20/2007	HepaLife announces appointment of Senior Medical Device and Healthcare Executive to the Board of Directors.
02/20/2007	Positive Research Findings Accelerate HepaLife's Development of Artificial Liver Device.
02/05/2007	Internationally Renowned Expert in Artificial Liver Device Development Joins HepaLife
01/22/2007	HepaLife Surpasses Major Milestone in Cell-Based Vaccine Development for Avian Influenza
01/16/2007	Pioneering Vaccine and Cell Culture Expert Joins HepaLife to Expedite Development of Avian Flu Vaccine
12/18/2006	Favorable Research Outcomes Prompt Expansion of HepaLife's Influenza Vaccine Initiative.
12/04/2006	HepaLife's Patented 'PBS-1' Cells for Avian Influenza Vaccine Achieve FDA's Early Guidance Research Objective.
11/20/2006	U.S. Officials Warn of 'Pandemic' Avian Influenza & Urgent Need for Cell-Based Vaccines, HepaLife's Primary Target.
10/03/2006	Mr. Frank Menzler Appointed as President and CEO of HepaLife.
08/15/2006	Dr. Paul Coussens Joins HepaLife's Scientific Advisory Board.
07/24/2006	HepaLife Targets Avian Flu: New Report Alerts Senior State Officials and Governors to Pandemic Influenza.
07/10/2006	HepaLife Enters Into Exclusive License Agreement for Development of New Flu Vaccines.
06/13/2006	HepaLife's Liver Cells Detect Acetaminophen Poisoning, A Leading Cause of Liver Failure.
05/30/2006	HepaLife Achieves Major Cell Biology Objective in Artificial Liver Device Research
05/22/2006	HepaLife's Liver Cell Function Plays Vital Role in Toxic, Brain Damaging Disease - a New Priority for NIH.
04/26/2006	HepaLife's Artificial Liver Research Passes Critical Human Plasma Milestone.
03/09/2006	HepaLife To Accelerate Research Activities And Bolster Management and Research Teams.
10/05/2005	Positive Results from Latest Experiments Released by HepaLife's Collaborating USDA Research Team.
09/19/2005	Important Room Temperature Storage Results To Be Released By HepaLife's Collaborating USDA Research Team.
08/12/2005	HepaLife Announces Appointment Of New President and Chief Executive Officer.
07/11/2005	HepaLife to Obtain Up to $15,000,000 in Equity Financing.
05/24/2005	Emergency Medicine Specialist at Front Lines of Adverse Drug Reactions & Acute Liver Failure Joins HepaLife to Assist Ongoing Development of Artificial Liver Device & Hepatotoxicity Testing Platform.
04/11/2005	HepaLife Surpasses Research Objectives: Continues to Advance Optimization of Proprietary Liver Cell Line for Final Use in Artificial Liver Device.
03/23/2005	Drug Complaints Reach Record High at US Food & Drug Administration
02/22/2005	HepaLife Announces Addition of Toxicology Scientist, to Develop Testing Platform for Liver Toxicity - the Leading Cause of Drug Withdrawals from Clinical Use.
02/02/2005	HepaLife to Expand Research Team
01/18/2005	HepaLife Comments on Federal Legislation Created to Facilitate the Commercialization of Technologies Developed by Federal Laboratories.
01/04/2005	NIH Issues Research Action Plan for Funding
12/15/2004	Drug induced liver injury expected to increase with almost half of all Americans now using prescription drugs.
12/08/2004	Renowned Organ Transplant Surgeon and Widely- Published Liver Expert to Assist Ongoing Development of HepaLife's Proprietary Artificial Liver Device
09/22/2004	Proprietary Liver Cell Line Performs Beyond Expectations
08/09/2004	Professor Dr. med. Michael Ott Joins HepaLife Scientific Advisory Board
08/02/2004	Dr. Ayesha Mahmood Joins Research Team
07/06/2004	HepaLife Receives Approval for Trading on Frankfurt Stock Exchange
06/15/2004	HepaLife Announces Formation of Distinguished Scientific Advisory Board
06/01/2004	HepaLife Announces Expansion and Extension of Cooperative Research Agreement
05/14/2004	HepaLife Expands into Developing Technology for Hepatotoxicity, the Most Common Reason Cited for the Withdrawal of an Approved Drug, Pre-Clinical Drug Failures, and for Refusal of Drug Approval by the FDA
04/14/2004	HepaLife Approved for Listing on Berlin Bremen Exchange
01/07/2004	HepaLife Announces Results of First Phase Research
12/17/2003	HepaLife to Release Latest Research Results
11/20/2003	HepaLife appoints Mr. Jasvir S. Kheleh as Director
10/07/2003	Hepatitis Now More Prevalent Than AIDS; HepaLife Developing Artificial Liver in Response to Growing Base of Liver Disease Sufferers
09/23/2003	Mr. Arian Soheili Appointed as Director and New President & CEO of HepaLife
09/03/2003	Dr. Mark A. Saarinen Joins Research Team
08/04/2003	Alcohol Abuse Major Cause of Liver Disease
07/29/2003	Scope of HepaLife's Artificial Liver Research
07/24/2003	Thornhill Advisors Engaged as Media Relations Counsel
07/21/2003	25 Million Americans Afflicted With Liver Disease
07/02/2003	HepaLife Initiates I.R. Program

A free reader for the PDF format (Adobe Acrobat) can be download and installed by clicking the link below and following instructions: Adobe® Acrobat® Reader (Free Download)

Send Page to a Friend Investor Alerts